Dr. Reddy's Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Dr. Reddy's Laboratories has a total shareholder equity of ₹294.6B and total debt of ₹27.0B, which brings its debt-to-equity ratio to 9.2%. Its total assets and total liabilities are ₹415.3B and ₹120.7B respectively. Dr. Reddy's Laboratories's EBIT is ₹65.6B making its interest coverage ratio -86.9. It has cash and short-term investments of ₹94.6B.
Key information
9.2%
Debt to equity ratio
₹26.97b
Debt
Interest coverage ratio | -86.9x |
Cash | ₹94.63b |
Equity | ₹294.63b |
Total liabilities | ₹120.67b |
Total assets | ₹415.30b |
Recent financial health updates
Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly
Jul 12Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet
Oct 21Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt
Jul 14Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Apr 11These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well
Jan 10Is Dr. Reddy's Laboratories (NSE:DRREDDY) A Risky Investment?
Sep 28Recent updates
If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Aug 19Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
Aug 01The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet
Jul 30Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly
Jul 12Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
Jun 23Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings
Jun 20Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00
May 26Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
May 10With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
May 06There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding
Apr 18Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 02Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?
Jan 19Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E
Jan 01Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet
Oct 21If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Oct 03Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt
Jul 14Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
Jun 24Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year
Jun 10Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
May 27Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00
May 13Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Apr 11If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Mar 06These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well
Jan 10If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Dec 05Is Dr. Reddy's Laboratories (NSE:DRREDDY) A Risky Investment?
Sep 28Do Dr. Reddy's Laboratories' (NSE:DRREDDY) Earnings Warrant Your Attention?
Aug 17Financial Position Analysis
Short Term Liabilities: DRREDDY's short term assets (₹269.2B) exceed its short term liabilities (₹105.7B).
Long Term Liabilities: DRREDDY's short term assets (₹269.2B) exceed its long term liabilities (₹15.0B).
Debt to Equity History and Analysis
Debt Level: DRREDDY has more cash than its total debt.
Reducing Debt: DRREDDY's debt to equity ratio has reduced from 22.2% to 9.2% over the past 5 years.
Debt Coverage: DRREDDY's debt is well covered by operating cash flow (158.3%).
Interest Coverage: DRREDDY earns more interest than it pays, so coverage of interest payments is not a concern.